Wall Street brokerages expect that Johnson & Johnson (NYSE:JNJ) will report $20.09 billion in sales for the current quarter, Zacks reports. Four analysts have provided estimates for Johnson & Johnson’s earnings, with estimates ranging from $19.96 billion to $20.22 billion. Johnson & Johnson posted sales of $20.35 billion in the same quarter last year, which suggests a negative year-over-year growth rate of 1.3%. The firm is expected to issue its next quarterly earnings report on Tuesday, October 15th.
According to Zacks, analysts expect that Johnson & Johnson will report full year sales of $81.51 billion for the current fiscal year, with estimates ranging from $81.23 billion to $81.99 billion. For the next fiscal year, analysts forecast that the business will report sales of $85.43 billion, with estimates ranging from $84.23 billion to $86.01 billion. Zacks Investment Research’s sales calculations are an average based on a survey of sell-side analysts that follow Johnson & Johnson.
Johnson & Johnson (NYSE:JNJ) last released its earnings results on Tuesday, July 16th. The company reported $2.58 EPS for the quarter, topping analysts’ consensus estimates of $2.42 by $0.16. Johnson & Johnson had a return on equity of 38.63% and a net margin of 20.08%. The firm had revenue of $20.56 billion for the quarter, compared to analysts’ expectations of $20.39 billion. During the same period in the prior year, the firm posted $2.10 earnings per share. The company’s quarterly revenue was down 1.3% on a year-over-year basis.
A number of research analysts have recently issued reports on the company. Barclays assumed coverage on Johnson & Johnson in a report on Friday, June 21st. They set a “hold” rating and a $140.00 price target on the stock. Credit Suisse Group set a $156.00 price target on Johnson & Johnson and gave the company a “buy” rating in a report on Thursday, July 18th. Royal Bank of Canada reaffirmed a “buy” rating on shares of Johnson & Johnson in a report on Tuesday, July 16th. Wells Fargo & Co reaffirmed an “outperform” rating and set a $157.00 price target (up from $152.00) on shares of Johnson & Johnson in a report on Monday, May 6th. Finally, Bank of America reaffirmed a “hold” rating and set a $150.00 price target on shares of Johnson & Johnson in a report on Tuesday, July 16th. Five equities research analysts have rated the stock with a hold rating and eight have given a buy rating to the company. Johnson & Johnson has an average rating of “Buy” and an average target price of $148.56.
NYSE JNJ opened at $130.54 on Friday. Johnson & Johnson has a 12 month low of $121.00 and a 12 month high of $148.99. The stock has a market cap of $348.11 billion, a P/E ratio of 15.96, a P/E/G ratio of 2.23 and a beta of 0.69. The stock’s fifty day moving average price is $134.10 and its 200-day moving average price is $136.70. The company has a current ratio of 1.33, a quick ratio of 1.04 and a debt-to-equity ratio of 0.46.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, September 10th. Stockholders of record on Tuesday, August 27th will be issued a dividend of $0.95 per share. This represents a $3.80 dividend on an annualized basis and a dividend yield of 2.91%. The ex-dividend date of this dividend is Monday, August 26th. Johnson & Johnson’s payout ratio is currently 46.45%.
In other Johnson & Johnson news, Director Marillyn A. Hewson purchased 3,000 shares of the stock in a transaction dated Tuesday, June 11th. The shares were purchased at an average cost of $139.68 per share, with a total value of $419,040.00. Following the completion of the acquisition, the director now directly owns 3,000 shares in the company, valued at approximately $419,040. The transaction was disclosed in a filing with the SEC, which is available at the SEC website. Corporate insiders own 0.23% of the company’s stock.
Hedge funds have recently bought and sold shares of the business. Billeaud Capital Management Inc. lifted its holdings in Johnson & Johnson by 0.4% in the second quarter. Billeaud Capital Management Inc. now owns 44,014 shares of the company’s stock valued at $6,130,000 after acquiring an additional 169 shares during the period. Archford Capital Strategies LLC lifted its holdings in Johnson & Johnson by 11.2% in the second quarter. Archford Capital Strategies LLC now owns 21,997 shares of the company’s stock valued at $3,064,000 after acquiring an additional 2,211 shares during the period. Hanson & Doremus Investment Management lifted its holdings in Johnson & Johnson by 2.8% in the second quarter. Hanson & Doremus Investment Management now owns 13,376 shares of the company’s stock valued at $1,863,000 after acquiring an additional 370 shares during the period. Freestone Capital Holdings LLC lifted its holdings in Johnson & Johnson by 8.3% in the fourth quarter. Freestone Capital Holdings LLC now owns 25,526 shares of the company’s stock valued at $3,294,000 after acquiring an additional 1,954 shares during the period. Finally, Foster Victor Wealth Advisors LLC lifted its holdings in Johnson & Johnson by 41.7% in the second quarter. Foster Victor Wealth Advisors LLC now owns 9,520 shares of the company’s stock valued at $1,342,000 after acquiring an additional 2,802 shares during the period. 67.35% of the stock is currently owned by institutional investors.
About Johnson & Johnson
Johnson & Johnson, together with its subsidiaries, researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DABAO, JOHNSON'S Adult, LE PETITE MARSEILLAIS, NEUTROGENA, and OGX brands; over-the-counter medicines, including acetaminophen products under the TYLENOL brand; cold, flu, and allergy products under the SUDAFED brand; allergy products under the BENADRYL and ZYRTEC brands; ibuprofen products under the MOTRIN IB brand; and acid reflux products under the PEPCID brand.
See Also: Portfolio Manager
For more information about research offerings from Zacks Investment Research, visit Zacks.com
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.